Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:TCRR TCR2 Therapeutics (TCRR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About TCR2 Therapeutics Stock (NASDAQ:TCRR) 30 days 90 days 365 days Advanced Chart Ad Stansberry ResearchPost-Election Bitcoin WarningAccording to the man who has called nearly every bubble of the last 25 years, Bitcoin owners should get ready to pay back all the gains they've seen the last few months... Click here to see Dan's full warning (and his potential solution) Get TCR2 Therapeutics alerts:Sign Up Key Stats Today's Range$1.48▼$1.6350-Day Range$1.48▼$1.9852-Week Range$0.82▼$3.88Volume3.91 million shsAverage Volume494,777 shsMarket Capitalization$58.10 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewTCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA.Read More… Post-Election Bitcoin Warning (Ad)According to the man who has called nearly every bubble of the last 25 years, Bitcoin owners should get ready to pay back all the gains they've seen the last few months... Click here to see Dan's full warning (and his potential solution) Receive TCRR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TCR2 Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TCRR Stock News HeadlinesPoseida Therapeutics Inc Ordinary Shares PSTXFebruary 25, 2024 | morningstar.comDICE Therapeutics Inc.June 20, 2023 | wsj.comPost-Election Bitcoin WarningAccording to the man who has called nearly every bubble of the last 25 years, Bitcoin owners should get ready to pay back all the gains they've seen the last few months... November 14, 2024 | Stansberry Research (Ad)Adaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy CompanyJune 1, 2023 | finance.yahoo.comTCR2 Therapeutics Insider Trades Send a SignalMay 16, 2023 | benzinga.comRecap: TCR2 Therapeutics Q1 EarningsMay 12, 2023 | msn.com10-Q: TCR2 THERAPEUTICS INC.May 11, 2023 | marketwatch.comTCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 11, 2023 | finance.yahoo.comSee More Headlines TCRR Stock Analysis - Frequently Asked Questions How were TCR2 Therapeutics' earnings last quarter? TCR2 Therapeutics Inc. (NASDAQ:TCRR) posted its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by $0.06. When did TCR2 Therapeutics IPO? TCR2 Therapeutics (TCRR) raised $76 million in an initial public offering (IPO) on Thursday, February 14th 2019. The company issued 5,000,000 shares at $14.55-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and China Renaissance were co-managers. What other stocks do shareholders of TCR2 Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that TCR2 Therapeutics investors own include Block (SQ), Digital Turbine (APPS), Palantir Technologies (PLTR), CrowdStrike (CRWD), Okta (OKTA), Vuzix (VUZI) and SoFi Technologies (SOFI). Company Calendar Last Earnings11/10/2021Today11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:TCRR CUSIPN/A CIK1750019 Webwww.tcr2.com Phone(617) 949-5200FaxN/AEmployees137Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-151,820,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-97.81% Return on Assets-69.35% Debt Debt-to-Equity RatioN/A Current Ratio2.96 Quick Ratio2.96 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.58 per share Price / Book0.57Miscellaneous Outstanding Shares39,260,000Free Float29,443,000Market Cap$58.10 million OptionableNot Optionable Beta1.95 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report This page (NASDAQ:TCRR) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | SponsoredNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TCR2 Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TCR2 Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.